Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2013, Article ID 651902, 5 pages
http://dx.doi.org/10.1155/2013/651902
Case Report

Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide

Hematology & Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Iwate 020-8505, Japan

Received 25 January 2013; Accepted 3 March 2013

Academic Editors: E. Arellano-Rodrigo, K. Konstantopoulos, M.-C. Kyrtsonis, R. Lowenthal, and Y. Matsukawa

Copyright © 2013 Shigeki Ito et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. K. Kumar, S. V. Rajkumar, A. Dispenzieri et al., “Improved survival in multiple myeloma and the impact of novel therapies,” Blood, vol. 111, no. 5, pp. 2516–2520, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Brenner, A. Gondos, and D. Pulte, “Recent major improvement in long-term survival of younger patients with multiple myeloma,” Blood, vol. 111, no. 5, pp. 2521–2526, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Y. Kristinsson, O. Landgren, P. W. Dickman, A. R. Derolf, and M. Björkholm, “Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003,” Journal of Clinical Oncology, vol. 25, no. 15, pp. 1993–1999, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Kastritis, K. Zervas, A. Symeonidis et al., “Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG),” Leukemia, vol. 23, no. 6, pp. 1152–1157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. M. A. Dimopoulos, K. Zervas, G. Kouvatseas et al., “Thalidomide and dexamethasone combination for refractory multiple myeloma,” Annals of Oncology, vol. 12, no. 7, pp. 991–995, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. P. G. Richardson, P. Sonneveld, M. Schuster et al., “Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial,” Blood, vol. 110, no. 10, pp. 3557–3560, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. D. M. Weber, C. Chen, R. Niesvizky et al., “Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America,” New England Journal of Medicine, vol. 357, no. 21, pp. 2133–2142, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Dimopoulos, A. Spencer, M. Attal et al., “Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma,” New England Journal of Medicine, vol. 357, no. 21, pp. 2123–2132, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. M. H. Ma, H. H. Yang, K. Parker et al., “The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents,” Clinical Cancer Research, vol. 9, no. 3, pp. 1136–1144, 2003. View at Google Scholar · View at Scopus
  10. N. Mitsiades, C. S. Mitsiades, P. G. Richardson et al., “The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications,” Blood, vol. 101, no. 6, pp. 2377–2380, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Hideshima, D. Chauhan, Y. Shima et al., “Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy,” Blood, vol. 96, no. 9, pp. 2943–2950, 2000. View at Google Scholar · View at Scopus
  12. J. A. Blansfield, D. Caragacianu, H. R. Alexander III et al., “Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy,” Clinical Cancer Research, vol. 14, no. 1, pp. 270–280, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. E. van der Spek, A. C. Bloem, H. M. Lokhorst, B. van Kessel, L. Bogers-Boer, and N. W. C. J. van de Donk, “Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma,” Leukemia Research, vol. 33, no. 1, pp. 100–108, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. B. M. Augustson, G. Begum, J. A. Dunn et al., “Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party,” Journal of Clinical Oncology, vol. 23, no. 36, pp. 9219–9226, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. S. A. Schey, G. J. Morgan, K. Ramasamy et al., “The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study,” British Journal of Haematology, vol. 150, no. 3, pp. 326–333, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. N. W. C. J. van de Donk, S. Wittebol, M. C. Minnema, and H. M. Lokhorst, “Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone- refractory myeloma,” British Journal of Haematology, vol. 148, no. 2, pp. 335–337, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. D. E. Reece, G. P. Rodriguez, C. Chen et al., “Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma,” Journal of Clinical Oncology, vol. 26, no. 29, pp. 4777–4783, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Mele, A. Giannotta, S. Pinna et al., “Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide,” Leukemia and Lymphoma, vol. 51, no. 5, pp. 937–940, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. S. V. Rajkumar, J. L. Harousseau, B. Durie et al., “Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1,” Blood, vol. 117, no. 18, pp. 4691–4695, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. G. J. Morgan, F. E. Davies, W. M. Gregory et al., “Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation,” Blood, vol. 118, pp. 1231–1238, 2011. View at Publisher · View at Google Scholar
  21. G. Sidra, C. D. Williams, N. H. Russell, S. Zaman, B. Myers, and J. L. Byrne, “Multiple myeloma: combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma,” Haematologica, vol. 91, no. 6, pp. 862–863, 2006. View at Google Scholar · View at Scopus
  22. G. J. Morgan, S. A. Schey, P. Wu et al., “Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients,” British Journal of Haematology, vol. 137, no. 3, pp. 268–269, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Kropff, G. Bisping, E. Schuck et al., “Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma,” British Journal of Haematology, vol. 138, no. 3, pp. 330–337, 2007. View at Publisher · View at Google Scholar · View at Scopus